CD36 and hepatocellular carcinoma: Since patients with high CD36 and medium CD47 also showed clinical benefits from the VT1021 treatment, it was relevant to include this population in the analysis: 12 out of 13 indications had more than 60% of cases with either dual high levels of CD36/CD47 or high CD36/medium CD47, with HCC (50%) as the only exception (Fig. 2d).